Hospitals largely supportive of 2019 IPPS proposed rule

Fewer quality measures, a shorter reporting period for Meaningful Use requirements and an increase in uncompensated rate payments were all positives in the eyes of hospitals in their initial reaction to the proposed 2019 Medicare Inpatient Prospective Payment System (IPPS) rule.

The proposals for acute care and long-term care hospitals follow through on several CMS initiatives announced over the past year. For example, keeping with the spirit of the “Meaningful Measures” initiative, the proposed rule would eliminate 19 quality measures and “de-duplicate” another 21 across the agency’s value-based purchasing and quality programs.

Tom Nickels, American Hospital Association’s executive vice president of government relations, had predicted CMS would use their annual rules to push for progress on those initiatives and said the AHA is pleased with the initial attempts to loosen regulations and reduce administrative requirements.

“Specifically, we are pleased that in today’s proposed rule, the agency would permanently revoke the 25% Rule for long-term care hospitals,” Nickels wrote in a statement. “This will help ensure that patients get the care they need when they need it without facing arbitrary restrictions by non-patient-centered regulations. We are also encouraged that this year’s rule begins to implement the Administration’s ‘meaningful measures’ initiative, a streamlined approach to quality measurement that can help ensure programs are focused on those core issues that are most critical to providing high-quality care and improving patient outcomes.”

As far as payments go in the proposed payment rule, acute care hospitals would receive a 1.75 percent operating rate increase along with a $1.5 billion increase in uncompensated care payments compared to the current fiscal year—with the total IPPS increase totaling 3.4 percent when factoring in all changes in the rule.

“The proposed increase in critically needed funds to treat the uninsured as well as the reduction in regulatory burden will also help enhance access to quality care for all patients,” said Chip Kahn, president of the Federation of American Hospitals (FAH).

Kahn also praised CMS efforts “to empower with information about their medical records and costs of care,” referencing the proposed rule’s provisions on promoting interoperability as well as requiring hospitals to post standard prices for treatments online. Cletis Earlie, chair of the board of trustees for the College of Healthcare Information Management Executives (CHIME), praised the emphasis on interoperability and consideration of burdens caused by Meaningful Use, though he added a word of warning about moving too fast with some reforms.

“We continue to urge caution as CMS moves ahead with changes to ensure that they facilitate quality care and lead to measurable improvements,” Earle said in a statement.

On the IT side, Nickels and the AHA praised the “more flexible, performance-based approach” to Meaningful Use, which will now be renamed “Promoting Interoperability,” as well as limiting the reporting period to 90 days in 2019 and 2020.

The one negative Nickels found was CMS requiring the use of 2015 certified EHR technology (CEHRT) in 2019. Those standards have been delayed for several years and CMS chief medical officer Kate Goodrich said in March “we are not backing down” on requiring it starting in 2019.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel.